709,484 Shares in PROCEPT BioRobotics Corporation $PRCT Purchased by William Blair Investment Management LLC

William Blair Investment Management LLC acquired a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 709,484 shares of the company’s stock, valued at approximately $16,020,000. William Blair Investment Management LLC owned approximately 1.24% of PROCEPT BioRobotics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Johnson & Johnson bought a new position in PROCEPT BioRobotics during the 2nd quarter worth $8,082,263,000. B. Metzler seel. Sohn & Co. AG acquired a new stake in PROCEPT BioRobotics during the fourth quarter worth about $1,864,000. Pinnacle Associates Ltd. bought a new position in PROCEPT BioRobotics in the 4th quarter valued at about $3,876,000. DNB Asset Management AS raised its position in shares of PROCEPT BioRobotics by 213.9% in the 4th quarter. DNB Asset Management AS now owns 99,567 shares of the company’s stock valued at $3,132,000 after buying an additional 67,848 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of PROCEPT BioRobotics by 69.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 174,739 shares of the company’s stock worth $5,375,000 after acquiring an additional 71,832 shares during the period. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insider Activity

In related news, CEO Larry L. Wood purchased 23,900 shares of the stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 1,000 shares of company stock worth $28,480 in the last three months. 4.00% of the stock is currently owned by corporate insiders.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases of PROCEPT stock from February 28, 2024, through February 25, 2026. These announcements are largely duplicative investor-solicitation notices rather than new company disclosures. Kaplan Fox class-action deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT failed to disclose inventory problems, including excess customer inventory tied to late-quarter bulk discounts, while investors focused on handpiece sales as a measure of procedure demand. The allegations claim that later revelations led to a substantial stock decline, including an approximately 18% drop referenced in one notice and a decline of more than 75% from the class-period high in another. Hagens Berman PROCEPT class-action notice
• Negative Sentiment: The litigation introduces potential legal costs, reputational risk and further scrutiny of PROCEPT’s sales practices, inventory management and underlying procedure demand. The notices do not establish wrongdoing, and no new operational update or company response was provided in the supplied articles. Kahn Swick and Foti PROCEPT securities-fraud notice

PROCEPT BioRobotics Trading Up 4.6%

PRCT opened at $21.68 on Friday. The company has a market cap of $1.24 billion, a P/E ratio of -11.18 and a beta of 0.89. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average is $20.40 and its 200-day moving average is $24.20. PROCEPT BioRobotics Corporation has a 1-year low of $16.67 and a 1-year high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.PROCEPT BioRobotics’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) earnings per share. Equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Piper Sandler cut their target price on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Leerink Partners downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $31.00 to $29.00 in a report on Thursday, June 11th. William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, TD Cowen lowered their price target on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, PROCEPT BioRobotics presently has an average rating of “Hold” and an average price target of $28.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.